LORLATINIB seems to take its place strongly in the treatment of Non-Small Cell Lung cancer as a 3rd generation ALK gene fusion and ROS1 translocation inhibitor. After 1st generation Crizotinib, 2nd generation Ceritinib and Alectinib, 3rd generation ALK and Here is the ROS1 inhibitor. Crizotinib had very successful results, it accompanied our treatment with Ceritinib in resistant cases, and finally it outperformed Crizotinib, the cornerstone of the Alectinib ALk series.
Progress was very good and phase II data of LORATINIB are much better (18th IASLC World Conference on Lung Cancer (abstract OA 05.06). LORLATINIB 100mg in the study group, which included patients with brain metastases, with ALK gene fusion or ROS1 translocation, who did not receive treatment It has been reported that a response of over 90% was obtained with ALK (excellent results.) It shows high efficiency in both ALK resistant cases and cases with ROS1 translocation, easily penetrates the central system and has significant response rates against brain metastases.
Crizotinib was the only approved agent in patients with ROS1 translocation.It can be predicted that it will be superior to Crizotinib with its effectiveness in ALK resistance, and Ceritinib and Alectinib with its effectiveness in ROS1 translocation.
